The THUNDERBOLT^TM Computer Assisted Vacuum Thrombectomy (CAVT^TM) technology introduces modulated aspiration for acute ischemic stroke for the first time, enabling more rapid, complete clot removal

ALAMEDA, Calif., June 15, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, announced it has secured CE Mark in Europe for THUNDERBOLT™, further laying the groundwork for launching computer assisted vacuum thrombectomy (CAVT™) technology to address acute ischemic stroke globally. The company received U.S. Food and Drug Administration clearance last week.

The THUNDERBOLT ® Computer Assisted Vacuum Thrombectomy (CAVTTM) technology introduces modulated aspiration for acute ischemic stroke for the first time, enabling more rapid, complete clot removal

"Stroke is the second leading cause of death worldwide, and if a blood clot is not fully removed, there is an increased risk of serious complications, disability or death,". said Prof. Vincent Costalat, Head of Neuroradiology at Centre Hospitalier Universitaire, Montpellier, France. "I am really enthusiastic and eager to see what THUNDERBOLT will bring for patients. What I love in the system is that it brings intelligence to the vacuum."

Powered by the Penumbra ENGINE™, THUNDERBOLT introduces modulated aspiration to Penumbra's neuro thrombectomy portfolio, offering advanced CAVT technology designed to detect, fatigue, and completely ingest clot at the site of the occlusion.

"THUNDERBOLT is a culmination of two decades of research and innovation at Penumbra," said Shruthi Narayan, president of Penumbra. "By introducing CAVT to the neurovascular field in Europe, we are ushering in a new era of stroke management that will have a significant impact on patient care. We are the only company to offer CAVT technology across both vascular and neurovascular care as we are committed to transforming how life-threatening clots are treated from head-to-toe worldwide."

A recent analysis estimates that stroke mortality worldwide is projected to increase by 50% between 2020 to 2050ⁱ. As the only CAVT device available for stroke treatment in Europe, as well as the U.S., THUNDERBOLT represents a first-of-its-kind advancement in acute ischemic stroke care.

"THUNDERBOLT has the potential to shorten procedure times — improving patient safety, delivering better outcomes and streamlining care for the physicians who treat them," said Joan Kristensen, head of the Europe, Middle East and Africa region for Penumbra, Inc. "Bringing this technology to Europe is a significant milestone — and a reflection of Penumbra's ongoing commitment to putting the most advanced stroke care tools in the hands of physicians across the region."

THUNDERBOLT will be pre-packaged with one of Penumbra's market-leading catheters - RED™ 62, RED 68, RED 72 SILVER LABEL or RED 72 SILVER LABEL with SENDit™ technology.

About Penumbra

Penumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn and X.

Important Safety Information

Additional information about Penumbra's products can be located on Penumbra's website at https://www.penumbrainc.com/providers. Caution: Federal (USA) law restricts these devices to sale by or on the order of a physician. Prior to use, please refer to the Instructions for Use (IFU) for complete product indications, contraindications, warnings, precautions, potential adverse events, and detailed instructions for use. Please visit www.peninc.info/risk for the complete IFU Summary Statements. The clinical results presented herein are for informational purposes only and may not be predictive for all patients. Individual results may vary depending on patient-specific attributes and other factors.

Forward-Looking Statements

Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: the risk that the pending acquisition by Boston Scientific Corporation will not be completed in the expected timeframe or at all, including the risk that required regulatory approvals will not be obtained; potential adverse effects to our business during the pendency of the acquisition, such as employee departures or diversion of management's attention from our business; failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory or other assets; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; potential adverse regulatory actions; and the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2025, which we filed on February 25, 2026. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.

Contact

Jennifer Heth

Penumbra, Inc.

jheth@penumbrainc.com

510-995-9791

Parinaz Farzin

Merryman Communications

parinaz@merrymancommunications.com

310.600.6746

ⁱ "Pragmatic solutions to reduce the global burden of stroke: a World Stroke Organization–Lancet Neurology Commission". The Lancet. Accessed on November 13, 2025. https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00277-6/fulltext

Penumbra, Inc. Logo (PRNewsFoto/Penumbra, Inc.)

View original content to download multimedia:https://www.prnewswire.com/news-releases/penumbra-expands-cavt-for-stroke-to-europe-with-ce-mark-for-thunderbolt-302799886.html

SOURCE Penumbra, Inc.